Last reviewed · How we verify
Recombinant influenza vaccines
Recombinant influenza vaccines stimulate the immune system to produce antibodies and cellular immunity against influenza virus antigens produced through recombinant DNA technology.
Recombinant influenza vaccines stimulate the immune system to produce antibodies and cellular immunity against influenza virus antigens produced through recombinant DNA technology. Used for Seasonal influenza prevention in adults, Seasonal influenza prevention in pediatric populations.
At a glance
| Generic name | Recombinant influenza vaccines |
|---|---|
| Sponsor | Henry M. Jackson Foundation for the Advancement of Military Medicine |
| Drug class | Vaccine |
| Target | Influenza hemagglutinin (HA) and neuraminidase (NA) antigens |
| Modality | Biologic |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
These vaccines use recombinant hemagglutinin (HA) or other influenza surface antigens manufactured in cell culture or insect cells rather than grown in eggs or cultured virus. This approach allows for rapid production, reduced egg-dependency, and potentially improved immunogenicity. The recombinant antigens trigger both humoral and cellular immune responses to provide protection against seasonal influenza infection.
Approved indications
- Seasonal influenza prevention in adults
- Seasonal influenza prevention in pediatric populations
Common side effects
- Injection site pain or erythema
- Myalgia
- Headache
- Fatigue
- Low-grade fever
Key clinical trials
- A Study to Evaluate the Safety and Immunogenicity of Two Doses of DCVC H1 HA mRNA-LNP in Healthy Adults (PHASE1)
- pH1N1 Blinded Challenge Study (PHASE1)
- Phase 1/2 Study of a Plant-Based Seasonal Recombinant Trivalent VLP Influenza Vaccine (PHASE1, PHASE2)
- A Study of Modified mRNA Vaccines in Healthy Adults (PHASE1)
- Vaccine Responses in Patients With B Cell Malignancies (PHASE4)
- A Study on the Safety and Immunogenicity of Influenza, Respiratory Syncytial Virus, Human Metapneumovirus and Parainfluenza Vaccines in Adults 18 to 49 Years of Age. (PHASE1)
- Comparative Immunogenicity of Respiratory Virus Vaccines (CIRV2) Study (PHASE4)
- Efficacy, Immunogenicity and Safety of OVX836 Influenza Vaccine 480μg (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: